New Adult Vaccine Guards Against Pertussis
It may be flu and cold season, but it’s always a good time for providers to be on the lookout for pertussis (whooping cough). Symptoms mirror the common cold: runny nose, sneezing, mild fever, and coughing. The tip off is cough severity and duration.
Pertussis is a contagious respiratory tract infection. Left untreated, it can last more than 100 days and manifest into pneumonia. Although vaccination is recommended — (DTaP) at age 15-18 months and 4-6 years, (Tdap) at 11-12 years, and a (Td/Tdap) booster every 10 years for adults — pertussis continues to persist in the United States, with epidemic cycles every 3-4 years.
According to the Centers for Disease Control and Prevention’s (CDC’s) 2007 National Immunization Survey (NIS), an estimated 98 percent of adults 18-64 reported not receiving a whooping cough booster shot.
Regardless, the U.S. Food and Drug Administration (FDA) recently approved GlaxoSmitKine’s BOOSTRIX (tetanus toxoid and acellular pertussis vaccine, adsorbed) for use in adults 19-64.
Latest posts by admin aapc (see all)
- US gets the ball rolling on ICD-11 - August 16, 2019
- Message From Your Region 7 Representatives | October 2018 - October 24, 2018
- Message From Your Region 6 Representatives | October 2018 - October 24, 2018